WO2003085134A3 - Methods of diagnosing and treating colorectal cancer - Google Patents

Methods of diagnosing and treating colorectal cancer Download PDF

Info

Publication number
WO2003085134A3
WO2003085134A3 PCT/JP2003/004226 JP0304226W WO03085134A3 WO 2003085134 A3 WO2003085134 A3 WO 2003085134A3 JP 0304226 W JP0304226 W JP 0304226W WO 03085134 A3 WO03085134 A3 WO 03085134A3
Authority
WO
WIPO (PCT)
Prior art keywords
helad1
colorectal
colorectal cancer
gene
treatment
Prior art date
Application number
PCT/JP2003/004226
Other languages
French (fr)
Other versions
WO2003085134A2 (en
Inventor
Yusuke Nakamura
Yoichi Furukawa
Original Assignee
Japan President Univ Tokyo
Oncotherapy Science Inc
Yusuke Nakamura
Yoichi Furukawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan President Univ Tokyo, Oncotherapy Science Inc, Yusuke Nakamura, Yoichi Furukawa filed Critical Japan President Univ Tokyo
Priority to JP2003582311A priority Critical patent/JP2005521421A/en
Priority to EP03715738A priority patent/EP1492884A2/en
Priority to AU2003219563A priority patent/AU2003219563A1/en
Publication of WO2003085134A2 publication Critical patent/WO2003085134A2/en
Publication of WO2003085134A3 publication Critical patent/WO2003085134A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present application provides a human gene, HELAD1, whose expression is markedly elevated in a great majority of colorectal cancers as compared to corresponding non-cancerous tissues. Specifically, in investigating the mechanisms of colorectal carcinogenesis, genes regulated by adenomatous polyposis coli gene product (APC) were searched and the HELAD1 gene (helicase, APC down-regulated 1) was identified. A recombinant polypeptide representing the ATPases associated with cellular activities (AAA) domain of the HELAD1 product showed 3' to 5' helicase activity and exonuclease activity in vitro. HELAD1 was abundantly expressed in 16 of 20 colon cancers examined but hardly detectable in corresponding non-cancerous mucosae. Treatment of colon-cancer cells with antisense oligonucleotides suppressed its expression and induced apoptosis. This data demonstrates the importance of HELAD1 in colorectal carcinogenesis and its utility as a diagnostic marker of colorectal cancer. It further suggest that suppression of HELAD1 may be a promising therapeutic strategy in the treatment of colorectal cancer.
PCT/JP2003/004226 2002-04-05 2003-04-02 Methods of diagnosing and treating colorectal cancer WO2003085134A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2003582311A JP2005521421A (en) 2002-04-05 2003-04-02 Methods for diagnosing and treating colorectal cancer
EP03715738A EP1492884A2 (en) 2002-04-05 2003-04-02 Methods of diagnosing and treating colorectal cancer
AU2003219563A AU2003219563A1 (en) 2002-04-05 2003-04-02 Methods of diagnosing and treating colorectal cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37060402P 2002-04-05 2002-04-05
US60/370,604 2002-04-05

Publications (2)

Publication Number Publication Date
WO2003085134A2 WO2003085134A2 (en) 2003-10-16
WO2003085134A3 true WO2003085134A3 (en) 2004-04-15

Family

ID=28792043

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/004226 WO2003085134A2 (en) 2002-04-05 2003-04-02 Methods of diagnosing and treating colorectal cancer

Country Status (4)

Country Link
EP (1) EP1492884A2 (en)
JP (1) JP2005521421A (en)
AU (1) AU2003219563A1 (en)
WO (1) WO2003085134A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100028256A1 (en) 2006-11-09 2010-02-04 St Croix Brad Differential gene expression in physiological and pathological angiogenesis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024810A2 (en) * 1996-12-04 1998-06-11 Janssen Pharmaceutica N.V. Vertebrate homologues of unc-53 protein of c. elegans
DE19908423A1 (en) * 1999-02-26 2000-08-31 Deutsches Krebsforsch Protein involved in the development of the CNS
WO2002017947A2 (en) * 2000-08-30 2002-03-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Use of t proteins for the differential characterization and treatment of lesions and tumors of the nervous system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024810A2 (en) * 1996-12-04 1998-06-11 Janssen Pharmaceutica N.V. Vertebrate homologues of unc-53 protein of c. elegans
DE19908423A1 (en) * 1999-02-26 2000-08-31 Deutsches Krebsforsch Protein involved in the development of the CNS
WO2002017947A2 (en) * 2000-08-30 2002-03-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Use of t proteins for the differential characterization and treatment of lesions and tumors of the nervous system

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ISHIGURO HIDEYUKI ET AL: "Isolation of HELAD1, a novel human helicase gene up-regulated in colorectal carcinomas.", ONCOGENE. ENGLAND 12 SEP 2002, vol. 21, no. 41, 12 September 2002 (2002-09-12), pages 6387 - 6394, XP002258792, ISSN: 0950-9232 *
MERRILL R A ET AL: "A mammalian homolog of unc-53 is regulated by all-trans retinoic acid in neuroblastoma cells and embryos.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. UNITED STATES 19 MAR 2002, vol. 99, no. 6, 19 March 2002 (2002-03-19), pages 3422 - 3427, XP002258793, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
EP1492884A2 (en) 2005-01-05
AU2003219563A1 (en) 2003-10-20
JP2005521421A (en) 2005-07-21
AU2003219563A8 (en) 2003-10-20
WO2003085134A2 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
Lin et al. Curcumin inhibits SK-Hep-1 hepatocellular carcinoma cell invasion in vitro and suppresses matrix metalloproteinase-9 secretion
Gay-Mimbrera et al. Clinical and biological principles of cold atmospheric plasma application in skin cancer
Mills Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins
Cigna et al. Basal cell carcinoma: 10 years of experience
Coates et al. Cancer therapy beyond apoptosis: autophagy and anoikis as mechanisms of cell death
Abboud et al. Antitumor action of amygdalin on human breast cancer cells by selective sensitization to oxidative stress
Goding Melanocytes: the new Black
TR201903587T4 (en) Compounds for increasing telomerase activity.
Janjua et al. Spectrophotometric analysis of flavonoid–DNA binding interactions at physiological conditions
WO2002030268A3 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
AU5341696A (en) Biologically active peptides and compositions, their use
ATE430573T1 (en) PHARMAUCETIC COMPOSITION CONTAINING NITRATES SOURCE AND ACIDIFICANTS FOR THE TREATMENT OF OPEN WOUNDS AND BURNS
WO2006081158A3 (en) Predictive and therapeutic markers in overian cancer
WO2004073657A3 (en) Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases
WO2005095622A3 (en) c-met siRNA ADENOVIRUS VECTORS INHIBIT CANCER CELL GROWTH, INVASION AND TUMORIGENICITY
CN1382448A (en) Genetic switch medicine for treating tumor
DE69902523T2 (en) USE OF ERYTHROPOIETIN FOR TREATING MULTIPLE MYELOMA
Marasovic et al. In vitro and in vivo antitumour effects of phenylboronic acid against mouse mammary adenocarcinoma 4T1 and squamous carcinoma SCCVII cells
WO2005065361A3 (en) Compounds and compositions for treating dysproliferative diseases, and methods of use thereof
WO2004075835A3 (en) Methods for the treatment of renal cell carcinoma
WO2003085134A3 (en) Methods of diagnosing and treating colorectal cancer
Deveci Özkan et al. In vitro chemo-protective effect of Eisenia foetida coelomic fluid against histone deacetylase inhibitor-induced oxidative toxicity in breast cancer cells
Mackenzie Stem cells in oral mucosal epithelia
TR200101980T2 (en) Arilalkanoil derivatives, their preparation processes
PL2270159T3 (en) Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003582311

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003715738

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003715738

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003715738

Country of ref document: EP